Skip to main content
Top
Published in: Medical Oncology 2/2012

01-06-2012 | Original Paper

Association of follicular lymphoma risk with BRCA2 N372H Polymorphism in Slovak population

Authors: Ján Šalagovič, Lucia Klimčáková, Denisa Ilenčíková, Adriana Kafková

Published in: Medical Oncology | Issue 2/2012

Login to get access

Abstract

Follicular lymphoma (FL) is one of the most common Non-Hodgkin lymphoma (NHL) subtype. Only small number of studies concerning NHL and DNA reparation gene polymorphisms has been performed so far. Hence, we have assessed the effect of 4 selected polymorphisms with possible influence on risk of FL development in a case–control study in Slovak population. We have genotyped polymorphisms in the RAG1 (K820R), LIG4 (T9I), BRCA2 (N372H), and WRN (V114I) genes in 108 patients with histologically proven FL diagnosis and 127 healthy controls. For discrimination between the allelic variants, we have established the genotyping by real-time melting analysis of an unlabeled probe. The most notable finding was related to polymorphism N372H in the BRCA2 gene. Compared with the wild-type genotype (NN), the homozygous variant genotype (HH) was associated with an increased FL risk (OR = 2.91, 95% CI: 0.96–8.81), although on the borderline of statistical significance (P = 0.050). However, after stratification by gender and age, the FL risk was significantly increased in men with variant-containing genotypes (OR = 2.79, 95% CI: 1.20–6.45) and even severalfold significantly increased among men with homozygous variant BRCA2 genotype (OR = 21.18, 95% CI: 2.46–182.2). No significant associations with FL risk were identified for other polymorphisms.
Literature
1.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRef Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRef
2.
go back to reference Hartge P. Estimating the burden of disease and the benefits of prevention. Epidemiology. 2006;17(5):498–9.PubMedCrossRef Hartge P. Estimating the burden of disease and the benefits of prevention. Epidemiology. 2006;17(5):498–9.PubMedCrossRef
3.
go back to reference Hartge P, Wang SS. Overview of the etiology and epidemiology of lymphoma. In: Mauch PM, Armitage JO, Coiffier B, Dalla-Favera R, Harris NL, editors. Non-Hodgkin’s Lymphomas. Philadelphia: Lippincott Williams& Wilkins; 2004. p. 711–27. Hartge P, Wang SS. Overview of the etiology and epidemiology of lymphoma. In: Mauch PM, Armitage JO, Coiffier B, Dalla-Favera R, Harris NL, editors. Non-Hodgkin’s Lymphomas. Philadelphia: Lippincott Williams& Wilkins; 2004. p. 711–27.
4.
go back to reference Au WY, Gascoyne RD, Klasa RD, et al. Incidence and spectrum of non-Hodgkin lymphoma in Chinese migrants to British Columbia. Br J Haematol. 2005;128:792–6.PubMedCrossRef Au WY, Gascoyne RD, Klasa RD, et al. Incidence and spectrum of non-Hodgkin lymphoma in Chinese migrants to British Columbia. Br J Haematol. 2005;128:792–6.PubMedCrossRef
5.
go back to reference Iscovich J, Parkin DM. Risk of cancer in migrants and their descendants in Israel: I. Leukaemias and lymphomas. Int J Cancer. 1997;70:649–53.PubMedCrossRef Iscovich J, Parkin DM. Risk of cancer in migrants and their descendants in Israel: I. Leukaemias and lymphomas. Int J Cancer. 1997;70:649–53.PubMedCrossRef
6.
go back to reference Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol. 2006;7:27–38.PubMedCrossRef Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol. 2006;7:27–38.PubMedCrossRef
7.
go back to reference Wang SS, Slager SL, Brennan P, et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;109:3479–88.PubMedCrossRef Wang SS, Slager SL, Brennan P, et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;109:3479–88.PubMedCrossRef
8.
go back to reference Kuppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene. 2001;20:5580–94.PubMedCrossRef Kuppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene. 2001;20:5580–94.PubMedCrossRef
9.
go back to reference Dyer MJS. The pathogenetic role of oncogenes deregulated by chromosomal translocation in B-cell malignancies. Int J Hematol. 2003;77:315–20.PubMedCrossRef Dyer MJS. The pathogenetic role of oncogenes deregulated by chromosomal translocation in B-cell malignancies. Int J Hematol. 2003;77:315–20.PubMedCrossRef
10.
11.
go back to reference Bende RJ, Smit LA, van Noesel CJM. Molecular pathways in follicular lymphoma. Leukemia. 2006;21:18–29.PubMedCrossRef Bende RJ, Smit LA, van Noesel CJM. Molecular pathways in follicular lymphoma. Leukemia. 2006;21:18–29.PubMedCrossRef
12.
go back to reference Hill DA, Wang SS, Cerhan JR, et al. Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes. Blood. 2006;108:3161–7.PubMedCrossRef Hill DA, Wang SS, Cerhan JR, et al. Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes. Blood. 2006;108:3161–7.PubMedCrossRef
13.
go back to reference Papavasiliou FN, Schatz DG. Cell-cycle-regulated DNA double-stranded breaks in somatic hypermutation of immunoglobulin genes. Nature. 2000;408:216–21.PubMedCrossRef Papavasiliou FN, Schatz DG. Cell-cycle-regulated DNA double-stranded breaks in somatic hypermutation of immunoglobulin genes. Nature. 2000;408:216–21.PubMedCrossRef
14.
go back to reference Shen M, Zheng T, Lan Q, Zhang Y, Zahm SH, Wang SS, et al. Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut. Hum Genet. 2006;119:659–68.PubMedCrossRef Shen M, Zheng T, Lan Q, Zhang Y, Zahm SH, Wang SS, et al. Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut. Hum Genet. 2006;119:659–68.PubMedCrossRef
15.
go back to reference Smedby KE, Lindgren CM, Hjalgrim H, Humphreys K, Schollkopf C, Chang ET, et al. Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma. Cancer Epidemiol Biomarkers Prev. 2006;15:258–65.PubMedCrossRef Smedby KE, Lindgren CM, Hjalgrim H, Humphreys K, Schollkopf C, Chang ET, et al. Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma. Cancer Epidemiol Biomarkers Prev. 2006;15:258–65.PubMedCrossRef
16.
go back to reference Wu X, Gu J, Grossman HB, et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cellcycle-control genes. Am J Hum Genet. 2006;78(3):464–79.PubMedCrossRef Wu X, Gu J, Grossman HB, et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cellcycle-control genes. Am J Hum Genet. 2006;78(3):464–79.PubMedCrossRef
17.
go back to reference Roddam PL, Rollinson S, O’Driscoll M, et al. Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination. J Med Genet. 2002;39(12):900–5.PubMedCrossRef Roddam PL, Rollinson S, O’Driscoll M, et al. Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination. J Med Genet. 2002;39(12):900–5.PubMedCrossRef
18.
go back to reference Kuschel B, Auranen A, McBride S, et al. Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet. 2002;11(12):1399–407.PubMedCrossRef Kuschel B, Auranen A, McBride S, et al. Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet. 2002;11(12):1399–407.PubMedCrossRef
19.
go back to reference Figueroa JD, Malats N, Rothman N, et al. Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. Carcinogenesis. 2007;28(8):1788–93.PubMedCrossRef Figueroa JD, Malats N, Rothman N, et al. Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. Carcinogenesis. 2007;28(8):1788–93.PubMedCrossRef
20.
go back to reference Palli D, Falchetti M, Masala G, et al. Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case–control study in Tuscany, Central Italy. BMC Cancer. 2007;7:170.PubMedCrossRef Palli D, Falchetti M, Masala G, et al. Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case–control study in Tuscany, Central Italy. BMC Cancer. 2007;7:170.PubMedCrossRef
21.
go back to reference Hiom K, Melek M, Gellert M. DNAtransposition by the RAG1 and RAG2 proteins: a possible source of oncogenic translocations. Cell. 1998;94:463–70.PubMedCrossRef Hiom K, Melek M, Gellert M. DNAtransposition by the RAG1 and RAG2 proteins: a possible source of oncogenic translocations. Cell. 1998;94:463–70.PubMedCrossRef
22.
go back to reference Corneo B, Moshous D, Gungor T, et al. Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome. Blood. 2001;97:2772–6.PubMedCrossRef Corneo B, Moshous D, Gungor T, et al. Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome. Blood. 2001;97:2772–6.PubMedCrossRef
23.
go back to reference Villa A, Sobacchi C, Notarangelo LD, et al. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood. 2001;97:81–8.PubMedCrossRef Villa A, Sobacchi C, Notarangelo LD, et al. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood. 2001;97:81–8.PubMedCrossRef
24.
go back to reference Gao Y, Ferguson DO, Xie W, et al. Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. Nature. 2000;404:897–900.PubMedCrossRef Gao Y, Ferguson DO, Xie W, et al. Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. Nature. 2000;404:897–900.PubMedCrossRef
25.
go back to reference Healey CS, Dunning AM, Teare MD, et al. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet. 2000;26:362–4.PubMedCrossRef Healey CS, Dunning AM, Teare MD, et al. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet. 2000;26:362–4.PubMedCrossRef
26.
go back to reference Spurdle AB, Hopper JL, Chen X, et al. The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years. Cancer Epidemiol Biomarkers Prev. 2002;11:413–6.PubMed Spurdle AB, Hopper JL, Chen X, et al. The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years. Cancer Epidemiol Biomarkers Prev. 2002;11:413–6.PubMed
27.
go back to reference Auranen A, Spurdle AB, Chen X, et al. BRCA2 Arg372His polymorphism and epithelial ovarian cancer risk. Int J Cancer. 2003;103:427–30.PubMedCrossRef Auranen A, Spurdle AB, Chen X, et al. BRCA2 Arg372His polymorphism and epithelial ovarian cancer risk. Int J Cancer. 2003;103:427–30.PubMedCrossRef
28.
go back to reference Wenham RM, Schildkraut JM, McLean K, et al. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. Clin Cancer Res. 2003;9:4396–403.PubMed Wenham RM, Schildkraut JM, McLean K, et al. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. Clin Cancer Res. 2003;9:4396–403.PubMed
29.
go back to reference Cox DG, Hankinson SE, Hunter DJ. No association between BRCA2 N372H and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14:1353–4.PubMedCrossRef Cox DG, Hankinson SE, Hunter DJ. No association between BRCA2 N372H and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14:1353–4.PubMedCrossRef
30.
go back to reference The Breast Cancer Linkage Consortium. Cancer Risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91:1310–6.CrossRef The Breast Cancer Linkage Consortium. Cancer Risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91:1310–6.CrossRef
31.
go back to reference Scott K, Adamson PJ, Barrans SL, Worrillow LJ, et al. RAG1 and BRCA2 polymorphisms in non-Hodgkin lymphoma. Blood. 2007;109(12):552–3.CrossRef Scott K, Adamson PJ, Barrans SL, Worrillow LJ, et al. RAG1 and BRCA2 polymorphisms in non-Hodgkin lymphoma. Blood. 2007;109(12):552–3.CrossRef
32.
go back to reference Fuks F, Milner J, Kouzarides T. BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene. 1998;17:2531–4.PubMedCrossRef Fuks F, Milner J, Kouzarides T. BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene. 1998;17:2531–4.PubMedCrossRef
33.
go back to reference Orwoll E, Lambert LC, Marshall LM, et al. Testosterone and estradiol among older men. J Clin Endocrinol Metab. 2006;91:1336–44.PubMedCrossRef Orwoll E, Lambert LC, Marshall LM, et al. Testosterone and estradiol among older men. J Clin Endocrinol Metab. 2006;91:1336–44.PubMedCrossRef
34.
go back to reference Zhoucun A, Zhang S, Yang Y, et al. The common variant N372H in BRCA2 gene may be associated with idiopathic male infertility with azoospermia or severe oligozoospermia. Eur J Obstet Gynecol Reprod Biol. 2006;124:61–4.PubMedCrossRef Zhoucun A, Zhang S, Yang Y, et al. The common variant N372H in BRCA2 gene may be associated with idiopathic male infertility with azoospermia or severe oligozoospermia. Eur J Obstet Gynecol Reprod Biol. 2006;124:61–4.PubMedCrossRef
35.
go back to reference Ozgenc A, Loeb LA. Current advances in unraveling the function of the Werner syndrome protein. Mutat Res. 2005;577(1–2):237–51.PubMed Ozgenc A, Loeb LA. Current advances in unraveling the function of the Werner syndrome protein. Mutat Res. 2005;577(1–2):237–51.PubMed
36.
go back to reference Goto M, Miller RW, Ishikawa Y, Sugano H. Excess of rare cancers in Werner syndrome. Cancer Epidemiol Biomarkers Prev. 1996;5:239–46.PubMed Goto M, Miller RW, Ishikawa Y, Sugano H. Excess of rare cancers in Werner syndrome. Cancer Epidemiol Biomarkers Prev. 1996;5:239–46.PubMed
Metadata
Title
Association of follicular lymphoma risk with BRCA2 N372H Polymorphism in Slovak population
Authors
Ján Šalagovič
Lucia Klimčáková
Denisa Ilenčíková
Adriana Kafková
Publication date
01-06-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-9925-9

Other articles of this Issue 2/2012

Medical Oncology 2/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.